e-learning
resources
Vienna 2003
Monday 29.09.2003
Lung cancer biology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The role of CD40 molecule in human lung cancer and its application in immunotherapy
J. A. Huang, T. L. Wang, Y. M. Zhuang, Y. B. Zhu, T. Gu, X. G. Zhang (Suzhou, China)
Source:
Annual Congress 2003 - Lung cancer biology
Session:
Lung cancer biology
Session type:
Oral Presentation
Number:
1338
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. A. Huang, T. L. Wang, Y. M. Zhuang, Y. B. Zhu, T. Gu, X. G. Zhang (Suzhou, China). The role of CD40 molecule in human lung cancer and its application in immunotherapy. Eur Respir J 2003; 22: Suppl. 45, 1338
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
The clinical significance of CD40 molecule expressed on human lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 394s
Year: 2003
The effect of adhesion molecule CEACAM1 and chemokine receptor CXCR4 expression on prognosis of non-small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 324s
Year: 2005
Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy
Source: Eur Respir J, 53 (3) 1801562; 10.1183/13993003.01562-2018
Year: 2019
Toll-like receptor 3 is up-regulated and enhances anti-proliferative function in human non-small cell lung cancer
Source: Annual Congress 2008 - Lung cancer and other malignant diseases involving the lungs
Year: 2008
Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10
Source: Eur Respir J 2007; 30: 608-610
Year: 2007
Association of antiPD1 immunotherapy with immunogenic cell death-inducing chemotherapy in a murine model of squamous cell lung cancer
Source: International Congress 2018 – Lung cancer: from the bench to the bedside
Year: 2018
Microbial analysis in lung cancer according to PD-L1 level and immunotherapy response
Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research
Year: 2021
Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker
Source: International Congress 2019 – Biology of lung cancer
Year: 2019
Prognostic and potential therapeutic impact of prostate specific membrane antigen expression in non-small cell lung cancer
Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores
Year: 2018
Interleukin-17 enhances the net angiogenic potential and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis
Source: Eur Respir J 2004; 24: Suppl. 48, 79s
Year: 2004
CAR T-cell therapy for lung cancer
Source: International Congress 2017 – A novel approach to lung cancer
Year: 2017
Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer>
Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer
Year: 2021
The expression of PD-L1 on the lung cancer cell and its role in T cell anergy
Source: Eur Respir J 2007; 30: Suppl. 51, 289s
Year: 2007
The role of STAT3 in T-cell responses during the development of NSCLC
Source: International Congress 2017 – Lung cancer - basic science: the latest results from the bench
Year: 2017
XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Ras peptide-specific vaccination in patients with non-small cell lung cancer (NSCLC)
Source: Annual Congress 2006 - Lung cancer treatment
Year: 2006
The role of immunotherapy
Source: Annual Congress 2006 - PG7 - Paediatric respiratory medicine: allergy for paediatric pulmonologists
Year: 2006
Efficacy of local therapy for oligoprogressive disease after PD-1 blockade in advanced non-small cell lung cancer
Source: Virtual Congress 2021 – COVID-19 and management of lung cancer
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept